Q-omics provides the consensus-scored VENTXP2 profile across patient tissues and cancer cell-line models. VENTXP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, VENTXP2 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, VENTXP2 RNA expression shows 8,770 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LIHC, and TGCT as cancer lineages where VENTXP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VENTXP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VENTXP2 survival associations across molecular data types. VENTXP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VENTXP2 RNA expression–survival associations across cancer types. High VENTXP2 expression shows unfavorable associations in COAD, BRCA, LAML, LIHC, UCEC and LUAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for VENTXP2 RNA expression.
This table summarizes VENTXP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for VENTXP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VENTXP2 shows higher tumor expression in LIHC. The LIHC box plot shows higher VENTXP2 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .023).
This table shows molecular features associated with VENTXP2 in patient tissues and cancer cell lines. In patient samples, VENTXP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
